BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 9620105)

  • 1. Troglitazone in type II diabetes mellitus.
    Sparano N; Seaton TL
    Pharmacotherapy; 1998; 18(3):539-48. PubMed ID: 9620105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Troglitazone for non-insulin-dependent diabetes mellitus.
    Med Lett Drugs Ther; 1997 May; 39(1001):49-51. PubMed ID: 9164446
    [No Abstract]   [Full Text] [Related]  

  • 3. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
    Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
    Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
    Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
    N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
    Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of troglitazone in treating the insulin resistance syndrome.
    Granberry MC; Schneider EF; Fonseca VA
    Pharmacotherapy; 1998; 18(5):973-87. PubMed ID: 9758309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New oral therapies for type 2 diabetes.
    Purnell JQ; Hirsch IB
    Am Fam Physician; 1997 Nov; 56(7):1835-42. PubMed ID: 9371013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Troglitazone: a new class of oral antihyperglycemic for the treatment of type II diabetes.
    Teter ML
    Nurse Pract; 1997 Jul; 22(7):119-21. PubMed ID: 9253019
    [No Abstract]   [Full Text] [Related]  

  • 10. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
    Katoh S; Hata S; Matsushima M; Ikemoto S; Inoue Y; Yokoyama J; Tajima N
    Metabolism; 2001 Apr; 50(4):414-7. PubMed ID: 11288035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
    Johnson MD; Campbell LK; Campbell RK
    Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
    Plosker GL; Faulds D
    Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of troglitazone on insulin sensitivity.
    Henry RR
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S148-50. PubMed ID: 8894499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosiglitazone.
    Goldstein BJ
    Int J Clin Pract; 2000 Jun; 54(5):333-7. PubMed ID: 10954962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Troglitazone.
    Spencer CM; Markham A
    Drugs; 1997 Jul; 54(1):89-101; discussion 102. PubMed ID: 9211083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repaglinide in combination therapy.
    Moses R
    Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):33-8. PubMed ID: 12702006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.
    Kohlroser J; Mathai J; Reichheld J; Banner BF; Bonkovsky HL
    Am J Gastroenterol; 2000 Jan; 95(1):272-6. PubMed ID: 10638596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
    Scheen AJ; Lefèbvre PJ
    Diabetes Care; 1999 Sep; 22(9):1568-77. PubMed ID: 10480527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic management of diabetes mellitus.
    Mozersky RP
    J Am Osteopath Assoc; 1999 Dec; 99(12 Suppl):S15-9. PubMed ID: 10659525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus.
    Parker JC
    Adv Drug Deliv Rev; 2002 Nov; 54(9):1173-97. PubMed ID: 12393300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.